-
4 Undervalued Stocks To Watch For In April
Sunday, April 11, 2021 - 11:43am | 666Read More...EBay Inc (NASDAQ: EBAY), SunPower Corporation (NASDAQ: SPWR), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Tupperware Brands Corporation (NYSE: TUP) are four stocks considered technically undervalued this month. Investors may seek out undervalued stocks to invest in for the...
-
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Saturday, April 10, 2021 - 9:18am | 1134Read More...Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks. FDA news flow of the week was mostly bordering on the negative. ACADIA...
-
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Tuesday, April 6, 2021 - 5:36pm | 694Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...
-
The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
Saturday, April 3, 2021 - 9:11am | 1052Read More...Biotech stocks ended the holiday-shortened week ended April 1 in the green, catalyzed by the broader market rebound and a slew of company-specific news flow. Buoyed by hopes of a U.S. government infrastructure spending program, the S&P 500 Index closed above the 4,000 level for the first...
-
Why Did BofA Downgrade Bausch Health?
Wednesday, March 24, 2021 - 11:39am | 336Read More...There are challenges to value creation in the proposed separation of Bausch Health Companies Inc’s (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Securities. The Bausch Health Analyst: Jason Gerberry downgraded the rating for Bausch...
-
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
Saturday, March 20, 2021 - 9:52am | 1386Read More...Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in...
-
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Saturday, March 6, 2021 - 11:57am | 1376Read More...Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts. Morphic...
-
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Sunday, February 28, 2021 - 11:54am | 2039Read More...Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster. NME approvals for the month included EMD Serono's Tepmetko for treating adult patients with certain types of non-small cell lung cancer,...
-
Walmart Sued By Justice Department Over Alleged Role In Opioid Crisis
Wednesday, December 23, 2020 - 3:24am | 306Read More...The U.S. Department of Justice hit Walmart Inc (NYSE: WMT) with a lawsuit on Tuesday alleging that the retailer’s shortcomings led to a rise in the nation’s opioid crisis, according to the Wall Street Journal. What Happened: In the lawsuit, the Justice Department said that Walmart...
-
The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision
Saturday, December 19, 2020 - 2:29pm | 463Read More...Biotech stocks extended their weekly gains for the fourth straight week, thanks to broader market buoyancy, positive FDA decisions and vaccine news. In a widely expected decision, Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate was cleared for emergency use by the FDA. MacroGenics...
-
The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics
Sunday, December 13, 2020 - 10:14am | 1144Read More...Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences. Positive vaccine news continued to flow. Pfizer Inc. (NYSE: PFE) and BioNTech...
-
Moderna Says U.S. Has Committed To Another 100M Doses of COVID-19 Vaccine
Saturday, December 12, 2020 - 9:36am | 445Read More...Even as emergency use authorization came in late Friday for the COVID-19 vaccine from Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) announced a greater committment from the U.S. for its vaccine candidate, mRNA-1273. What Happened:...
-
IPO Outlook For The Week: Airbnb, DoorDash Lead Highly Anticipated Week
Sunday, December 6, 2020 - 11:43am | 1155Read More...The highly anticipated debuts of Airbnb and DoorDash are among the seven IPOs markets could see this coming week. Airbnb: Vacation rental company Airbnb is scheduled to go public on Thursday, Dec. 10 under the Nasdaq ticker symbol ABNB. The company plans to sell 51.9 million shares at a price...
-
Here Are The Types Of COVID-19 Tests You Can Take
Wednesday, December 2, 2020 - 9:54pm | 1487Read More...With the third wave of the coronavirus taking over the country, the US has seen more than 13,9 million confirmed cases and over 273,000 deaths so far, the New York Times has reported. According to Johns Hopkins data, the test-positivity rates have exceeded a World Health...
-
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
Saturday, November 28, 2020 - 2:08pm | 2521Read More...The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related...
